• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The journal of clinical psychiatry >Treatment of tardive dyskinesia with donepezil: a pilot study.
【24h】

Treatment of tardive dyskinesia with donepezil: a pilot study.

机译：多奈哌齐治疗迟发性运动障碍：一项前瞻性研究。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: Tardive dyskinesia (TD) remains a significant clinical problem for which there is no uniformly effective treatment. Earlier trials with acetylcholine precursors may have been disappointing because of underlying damage to striatal cholinergic neurons in patients with TD. In contrast, new cholinesterase inhibitors, developed for the treatment of dementia, may improve TD by directly increasing cholinergic synaptic transmission. METHOD: We conducted an 8-week open-label trial of donepezil in the treatment of TD. Ten patients with schizophrenia or schizoaffective disorder who received stable doses of antipsychotics and met DSM-IV criteria for TD were treated with donepezil, 5 to 10 mg/day, for 6 weeks after a 2-week baseline period. Changes in total Abnormal Involuntary Movement Scale (AIMS) scores measured every 2 weeks were assessed for significance. Patients were also assessed using the Brief Psychiatric Rating Scale, the Mini-Mental State Examination, the Barnes Akathisia Scale, and the Simpson-Angus Scale. RESULTS: Total AIMS scores decreased significantly (p = .0009), with no changes in other measures. Nine patients showed a positive response. Improvement was greatest in orofacial and upper extremity movements. No significant interactions were noted between the total AIMS scores and age (p > .29), duration of TD (p > .38), or duration of antipsychotic treatment (p > .14). CONCLUSION: Donepezil appeared to be effective in suppressing TD in this pilot study. However, placebo-controlled, double-blind studies are necessary before donepezil can be recommended as a treatment for TD.
机译：背景：迟发性运动障碍（TD）仍然是一个重要的临床问题，目前尚无统一有效的治疗方法。早期使用乙酰胆碱前体的试验可能令人失望，因为TD患者纹状体胆碱能神经元受到了潜在的损害。相反，为治疗痴呆症而开发的新型胆碱酯酶抑制剂可通过直接增加胆碱能突触传递来改善TD。方法：我们进行了多奈哌齐治疗TD的8周开放标签试验。在2周的基线期后，对10例接受稳定剂量的抗精神病药并达到DSM-IV TD标准的精神分裂症或精神分裂症患者进行5周至10 mg /天的多奈哌齐治疗，持续6周。每2周测量一次的总异常非自愿运动量表（AIMS）得分的变化被评估为显着性。还使用简短精神病评定量表，迷你精神状态检查量表，Barnes Akathisia量表和Simpson-Angus量表对患者进行评估。结果：AIMS总分显着下降（p = .0009），其他指标无变化。 9例患者显示阳性反应。口面部和上肢运动的改善最大。在AIMS总评分与年龄（p> .29），TD持续时间（p> .38）或抗精神病药物治疗的持续时间（p> .14）之间没有发现显着的相互作用。结论：多奈哌齐在这项初步研究中似乎有效抑制TD。但是，安慰剂对照的双盲研究对于推荐多奈哌齐治疗TD的治疗是必要的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号